Disclosed herein are a novel organometallic compound and an organic light-emitting diode including same. More specifically, an organometallic compound represented by [Chemical Formula 1] and an organic light-emitting diode including same are provided.

Provided is an organometallic compound of Chemical Formula 1: ##STR00001## wherein, in Chemical Formula 1: X is O, S, NH, or Se; R.sub.1 is —Si(R.sub.a)(R.sub.b)(R.sub.c), where R.sub.a, R.sub.b, and R.sub.c are hydrogen, deuterium, or a substituted or unsubstituted C.sub.1-10 alkyl; R.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen, deuterium, halogen, cyano, amino, a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkoxy, a substituted or unsubstituted C.sub.3-60 cycloalkyl, a substituted or unsubstituted c.sub.2-60 alkenyl, a substituted or unsubstituted C.sub.6-60 aryl, a substituted or unsubstituted C.sub.6-60 aryloxy, or a substituted or unsubstituted C.sub.2-60 heterocyclic group containing one or more heteroatoms selected from the group consisting of N, O and S; a and b are each 0 and 1, or 1 and 0, respectively; and n is 1 or 2,
and an organic light emitting device including the same.

Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II): ##STR00001##
Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.

The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer. ##STR00001##

Provided is an organometallic complex including a ligand L.sub.A having a structure represented by one of the following formulas ##STR00001##
and coordiated to Ir.

Disclosed herein are processes for dehydrogenation of an alkane to an alkene using an iridium pincer complex. In the dehydrogenation reactions, hydrogen that is co-formed during the process must be removed for the chemical reaction to proceed and to prevent the excess hydrogen from poisoning the catalyst. In one embodiment the process comprises providing an alkane feedstock comprising at least one alkane and contacting the alkane with an iridium pincer complex in the presence of a hydrogen acceptor selected from the group consisting of ethylene, propene, or mixtures to form an alkene product. The processes disclosed herein can accomplish facile, low-temperature transfer dehydrogenation of alkanes with unprecedented selectivities and TONs at a reasonable rate of conversion.

Platinum, palladium, and gold tetradentate metal complexes of Formulas I and II including indoloacridine.

##STR00001##

The complexes are suitable for use as phosphorescent or delayed fluorescent and phosphorescent emitters in display and lighting applications.

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.

Metal-assisted delayed fluorescent (MADF) emitters including cyclic tetradentate platinum (II) and palladium (II) complexes employing 8H-pyrido[3′,2′:4,5]-pyrrolo[3,2,1-de]acridine and its analogues. These complexes provide improved color purity and enhanced operational stability and are suitable for luminescent labels, emitters for organic light emitting diodes (OLEDs), and lighting applications.